For example, SIM0500, an IgG4-based TsAb targeting BCMA/GPRC5D/CD3, has demonstrated potent T-cell redirection and cytotoxicity against myeloma cells in preclinical models, including enhanced T-cell expansion, cytokine production, and lysis of tumor cells compared to bispecific formats. Here, TNFRSF17 is linked to plasma cell myeloma.